Does XTANDI Cause Malignant neoplasm progression? 235 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 235 reports of Malignant neoplasm progression have been filed in association with XTANDI. This represents 16.9% of all adverse event reports for XTANDI.
235
Reports of Malignant neoplasm progression with XTANDI
16.9%
of all XTANDI reports
110
Deaths
34
Hospitalizations
How Dangerous Is Malignant neoplasm progression From XTANDI?
Of the 235 reports, 110 (46.8%) resulted in death, 34 (14.5%) required hospitalization, and 1 (0.4%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for XTANDI. However, 235 reports have been filed with the FAERS database.
What Other Side Effects Does XTANDI Cause?
Death (234)
Fatigue (162)
Drug ineffective (158)
Prostatic specific antigen increased (94)
Nausea (69)
Asthenia (62)
Decreased appetite (56)
Dizziness (52)
Diarrhoea (51)
Back pain (41)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)